VTGN VistaGen Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VTGN

Price (delayed)

$0.3684

Market cap

$16.35M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.66

Enterprise value

$140,454

?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 3
Relative Valuation: Rel. Valuation: 11
Relative Profitability: Rel. Profitability: 22

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS ...

Highlights
VistaGen Therapeutics's revenue has surged by 97% QoQ
The gross profit has soared by 97% from the previous quarter
The net income has declined by 21% year-on-year but it has increased by 3% since the previous quarter
The equity has shrunk by 57% YoY and by 31% QoQ
VTGN's quick ratio is down by 50% year-on-year and by 20% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.vistagen.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of VTGN

VTGN stock price

How has the VistaGen Therapeutics stock price performed over time
Intraday
46.54%
1 week
59.76%
1 month
50.98%
1 year
-89.29%
YTD
-44.34%
QTD
63.01%

Financial performance

How have VistaGen Therapeutics's revenue and profit performed over time
Revenue
$2.5M
Gross profit
$2.5M
Operating income
-$69.66M
Net income
-$67.62M
Gross margin
100%
Net margin
-2,702.6%
VistaGen Therapeutics's revenue has surged by 97% QoQ
The gross profit has soared by 97% from the previous quarter
The operating margin has soared by 70% year-on-year and by 51% since the previous quarter
The company's net margin has surged by 69% YoY and by 51% QoQ

Price vs fundamentals

How does VTGN's price correlate with its fundamentals

Growth

What is VistaGen Therapeutics's growth rate over time

Valuation

What is VistaGen Therapeutics stock price valuation
P/E
N/A
P/B
0.62
P/S
6.33
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.06
VistaGen Therapeutics's EPS has increased by 9% from the previous quarter and by 7% YoY
The price to book (P/B) is 78% lower than the 5-year quarterly average of 1.9 and 48% lower than the last 4 quarters average of 0.8
The equity has shrunk by 57% YoY and by 31% QoQ
The price to sales (P/S) is 97% lower than the 5-year quarterly average of 134.7 and 93% lower than the last 4 quarters average of 58.1
VistaGen Therapeutics's revenue has surged by 97% QoQ

Efficiency

How efficient is VistaGen Therapeutics business performance
The ROE has plunged by 106% YoY and by 15% from the previous quarter
The company's return on assets has shrunk by 83% YoY and by 11% QoQ
The company's return on invested capital has shrunk by 82% YoY and by 7% QoQ
VistaGen Therapeutics's ROS has soared by 69% YoY and by 51% from the previous quarter

Dividends

What is VTGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VTGN.

Financial health

How did VistaGen Therapeutics financials performed over time
VTGN's quick ratio is down by 50% year-on-year and by 20% since the previous quarter
The current ratio has decreased by 49% YoY and by 16% from the previous quarter
The company's debt is 97% lower than its equity
The company's debt has shrunk by 67% YoY and by 25% QoQ
The equity has shrunk by 57% YoY and by 31% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.